帕陶氏症候群基因檢測市場規模、佔有率和成長分析:按檢測類型、檢測方法、檢體類型、最終用戶和地區分類 - 產業預測,2026-2033年
市場調查報告書
商品編碼
2160477

帕陶氏症候群基因檢測市場規模、佔有率和成長分析:按檢測類型、檢測方法、檢體類型、最終用戶和地區分類 - 產業預測,2026-2033年

Patau Syndrome Genetic Testing Market Size, Share, and Growth Analysis, By Test Type (Prenatal Testing, Postnatal Testing), By Testing Method, By Sample Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球帕陶氏症候群基因檢測市值為 2.856 億美元,預計到 2025 年將成長至 3.0959 億美元,到 2033 年將成長至 5.9024 億美元,在預測期(2026-2033 年)內複合年成長率為 8.4%。

隨著非侵入性產前檢測 (NIPT) 成為產科護理的標準流程,全球帕陶氏症候群基因檢測市場正經歷強勁成長。這一轉變,加上13號染色體三體症候群檢測的保險覆蓋範圍擴大,使得醫療機構能夠在不增加患者自付費用的情況下提供全面的檢測項目。檢查室自動化簡化了工作流程,縮短了周轉時間,並吸引了許多致力於為檢測方法開發產生寶貴數據的研究聯盟。此外,人工智慧 (AI) 的進步顯著提高了檢測準確性,增強了模式識別能力並最大限度地減少了誤判,從而能夠透過更精確的數據解讀實現更快的診斷。隨著產前篩檢的普及,市場對可靠的非侵入性檢測方案的需求不斷成長,預計收入將持續成長,尤其是在亞太地區的新興市場。

全球帕陶氏症候群基因檢測市場促進因素

民眾和醫療專業人員對帕陶氏症候群等遺傳疾病的認知不斷提高,顯著提升了早期檢測的需求,促使醫療機構將檢測納入標準的產前護理流程。隨著家庭尋求更明智的選擇,臨床醫生擴大推薦全面的篩檢方案,從而擴大了基因檢測公司的基本客群。此外,這種認知的提高也促使政策制定者擴大保險覆蓋範圍,透過提高基因檢測服務的可及性和社會接受度,促進了市場成長。這些努力也增強了人們對檢測準確性的信心,並推動了檢測在各個地區的廣泛應用。

全球帕陶氏症候群基因檢測市場的限制因素

全面的基因檢測費用高昂,對病患和醫療服務提供者都構成重大挑戰,尤其是在缺乏完善的保險報銷體系的地區。自付費用往往阻礙臨床醫生將這些檢測納入日常診療,導致他們只能專注於關鍵評估。這些經濟限制使得低收入者和小規模醫療機構難以獲得相關服務,最終阻礙了整體市場成長。此外,公共醫療機構面臨的預算限制也常常導致創新篩檢技術的延遲應用或選擇性採用。這些經濟障礙也限制了對有效服務提供所需的培訓和基礎設施的投資。

全球帕陶氏症候群基因檢測市場趨勢

全球帕陶氏症候群基因檢測市場正經歷顯著成長,這主要得益於醫療保健系統新生兒篩檢的日益普及。人們越來越認知到早期發現和早期療育的關鍵益處,帕陶氏症候群檢測也因此被納入普遍篩檢計畫。這項轉變不僅加快了兒童的識別,也提高了臨床管理和遺傳諮詢的品質。隨著公共衛生舉措強調全面的周產期護理,檢測實驗室正在不斷提升自身能力,並與醫療機構建立策略夥伴關係。這不僅擴大了其市場佔有率,也確保了已開發市場和新興市場對基因診斷服務的持續需求。

目錄

介紹

  • 調查目的
  • 市場定義和範圍

調查方法

  • 研究過程
  • 二級資料和一級資料的方法
  • 市場規模估算方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態及展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特的分析和影響
    • 競爭公司之間的競爭
    • 替代品的威脅
    • 買方的議價能力
    • 新進入者的威脅
    • 供應商的議價能力

關鍵市場分析

  • 關鍵成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 2025年市場魅力指數
  • PESTLE分析
  • 監理情勢

帕陶氏症候群基因檢測的全球市場規模:依檢測類型分類

  • 產前檢查
  • 產後檢查
  • 基因帶原檢測和遺傳風險檢測

帕陶氏症候群基因檢測的全球市場規模:依檢測方法分類

  • 非侵入性產前檢測
  • 核型分析
  • 螢光原位雜合反應(FISH)
  • 染色體微陣列
  • 其他

帕陶氏症候群基因檢測的全球市場規模:按檢體類型分類

  • 母體血
  • 羊水
  • 絨毛樣本
  • 血液和組織檢體

帕陶氏症候群基因檢測的全球市場規模:依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 研究和學術機構

帕陶氏症候群基因檢測的全球市場規模:按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭資訊

  • 前五大公司對比
  • 主要公司2025年的市場定位
  • 主要市場公司採取的策略
  • 近期市場趨勢
  • 企業市場占有率分析,2025 年
  • 主要公司的完整公司簡介
    • 公司詳情
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 銷售收入年比比較(2023-2025 年)

主要公司簡介

  • F. Hoffmann-La Roche Ltd.
  • QIAGEN NV
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Eurofins Scientific SE
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Invitae Corporation
  • Labcorp
  • Quest Diagnostics Incorporated
  • Centogene NV
  • PreventionGenetics LLC
  • GeneDx, LLC
  • Ambry Genetics Corporation
  • Fulgent Genetics, Inc.
  • Baylor Genetics

結論與建議

簡介目錄
Product Code: SQMIG35J2838

Global Patau Syndrome Genetic Testing Market size was valued at USD 285.6 Million in 2024 and is poised to grow from USD 309.59 Million in 2025 to USD 590.24 Million by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The Global Patau Syndrome Genetic Testing market is experiencing robust growth driven by the integration of Non-Invasive Prenatal Testing (NIPT) into standard obstetric care. This shift, coupled with insurance reimbursement for trisomy 13 testing, allows providers to offer comprehensive testing panels without increasing out-of-pocket expenses for patients. Automation in laboratories streamlines workflows, reducing turnaround times and attracting research consortia interested in generating valuable data for assay development. Furthermore, advancements in artificial intelligence are significantly improving test accuracy by enhancing pattern recognition and minimizing false calls, enabling faster diagnosis through better data interpretation. As prenatal screening expands, the market is witnessing increased demand for reliable, non-invasive testing options, positioning it for sustained revenue growth, particularly in emerging Asia-Pacific markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Patau Syndrome Genetic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Patau Syndrome Genetic Testing Market Segments Analysis

Global patau syndrome genetic testing market is segmented by test type, testing method, sample type, end user and region. Based on test type, the market is segmented into Prenatal Testing, Postnatal Testing and Carrier & Genetic Risk Testing. Based on testing method, the market is segmented into Non-Invasive Prenatal Testing, Karyotyping, Fluorescence In Situ Hybridization, Chromosomal Microarray and Other Molecular Tests. Based on sample type, the market is segmented into Maternal Blood, Amniotic Fluid, Chorionic Villus Samples and Blood & Tissue Samples. Based on end user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research & Academic Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Patau Syndrome Genetic Testing Market

The increasing awareness among both the public and healthcare professionals regarding genetic disorders like Patau syndrome significantly boosts the need for early detection, leading healthcare providers to integrate testing into standard prenatal care practices. As families look for ways to make informed choices, clinicians are more inclined to advocate for thorough screening options, thereby broadening the customer base for genetic testing manufacturers. Additionally, this heightened awareness motivates policymakers to endorse coverage initiatives, contributing to market growth by enhancing accessibility and societal acceptance of genetic testing services. Such initiatives also foster confidence in the accuracy of tests, promoting wider adoption across various regions.

Restraints in the Global Patau Syndrome Genetic Testing Market

The high costs associated with comprehensive genetic testing panels pose significant challenges for both patients and healthcare providers, particularly in areas lacking adequate reimbursement systems. The burden of out-of-pocket expenses often deters clinicians from incorporating these tests into regular practice, causing them to focus solely on critical assessments. This financial sensitivity limits access for low-income individuals and smaller healthcare facilities, which in turn hampers overall market growth. Furthermore, budgeting limitations faced by public health organizations often lead to postponed or selective adoption of innovative screening technologies. These economic obstacles also restrict investments in necessary training and infrastructure for effective service delivery.

Market Trends of the Global Patau Syndrome Genetic Testing Market

The Global Patau Syndrome Genetic Testing market is experiencing significant growth, fueled by the expanded adoption of newborn screening practices across healthcare systems. Increasing awareness of the critical benefits associated with early detection and intervention is prompting the integration of Patau syndrome testing into universal screening panels. This evolution not only accelerates the identification of affected infants but also enhances clinical management and genetic counseling for families. As public health initiatives emphasize comprehensive perinatal care, laboratories are enhancing their capabilities and forming strategic partnerships with healthcare providers, thereby broadening their market presence and ensuring sustained demand for genetic diagnostic services in both developed and emerging markets.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porter's Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitutes
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Patau Syndrome Genetic Testing Market Size by Test Type & CAGR (2026-2033)

  • Market Overview
  • Prenatal Testing
  • Postnatal Testing
  • Carrier & Genetic Risk Testing

Global Patau Syndrome Genetic Testing Market Size by Testing Method & CAGR (2026-2033)

  • Market Overview
  • Non-Invasive Prenatal Testing
  • Karyotyping
  • Fluorescence In Situ Hybridization
  • Chromosomal Microarray
  • Other Molecular Tests

Global Patau Syndrome Genetic Testing Market Size by Sample Type & CAGR (2026-2033)

  • Market Overview
  • Maternal Blood
  • Amniotic Fluid
  • Chorionic Villus Samples
  • Blood & Tissue Samples

Global Patau Syndrome Genetic Testing Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions

Global Patau Syndrome Genetic Testing Market Size & CAGR (2026-2033)

  • North America (Test Type, Testing Method, Sample Type, End User)
    • US
    • Canada
  • Europe (Test Type, Testing Method, Sample Type, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Test Type, Testing Method, Sample Type, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Test Type, Testing Method, Sample Type, End User)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Test Type, Testing Method, Sample Type, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Illumina, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Danaher Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific SE
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Myriad Genetics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Natera, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Invitae Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Labcorp
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Quest Diagnostics Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Centogene N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PreventionGenetics LLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneDx, LLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ambry Genetics Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fulgent Genetics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baylor Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations